Management of relapse after allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia: What is the best strategy?

We read the study of Schmidt et al. [1] with great interest, in which they retrospectively analyzed 215 patients with chronic myeloid leukemia (CML) who relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT). The patients were divided into three groups according to the treatment applied following posttransplant relapse; as patients receiving tyrosine kinase inhibitor (TKI) alone, cases with TKI  + donor lymphocyte infusion (DLI) combination arm, and DLI alone.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research